Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NNOX - Nano-X Imaging Ltd. So'nggi Yangiliklar | Finranks

Home

NNOX

N

Nano-X Imaging Ltd. (NNOX)

NGM – Real vaqt narxi. Valyuta: USD

2.21

-0.06 (-2.64%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.25

+0.04 (1.80%)

Bozordan keyin: Mar 27, 2026, 6:40 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

All You Need to Know About NanoX Imaging (NNOX) Rating Upgrade to Buy

All You Need to Know About NanoX Imaging (NNOX) Rating Upgrade to Buy

NanoX Imaging (NNOX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast

Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast

Agreement with Imperial Imaging strengthens Nanox's commercial rollout across the orthopedic-rich segment in six U.S. Southeast states.

Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina

Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide.

Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026

Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026

PETACH TIKVA, Israel, Feb. 17, 2026 - NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions in development at the European Congress of Radiology (ECR), taking place March 4-8, 2026 in Vienna, Austria.

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US

Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina

Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina

Collaboration with Adriamed drives commercial expansion and strengthens Nanox's regional leadership Engagement supports continued growth across multiple European markets, following recent collaborations in Greece, Romania, Czech Republic and France PETACH TIKVA, ISRAEL – January 14, 2026 – Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a new collaboration with Adriamed d.o.o.

Nano-X Imaging Remains Underwhelming Despite Recent Wins

Nano-X Imaging Remains Underwhelming Despite Recent Wins

Nano-X Imaging remains a 'sell' due to weak revenue growth, worsening losses, and limited traction in its core business. NNOX's advanced imaging technology and AI offerings have yet to translate into significant sales, with most revenue still from teleradiology services. Recent partnerships and acquisitions, including VasoHealthcare IT and European distribution deals, offer potential but lack a clear financial impact.

Videolar

No Data

There is no data to display

Press-relizlar

Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast

Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast

Agreement with Imperial Imaging strengthens Nanox's commercial rollout across the orthopedic-rich segment in six U.S. Southeast states.

Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina

Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide.

Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026

Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026

PETACH TIKVA, Israel, Feb. 17, 2026 - NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions in development at the European Congress of Radiology (ECR), taking place March 4-8, 2026 in Vienna, Austria.

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US